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Abstract
Background: Psychotic conditions and especially schizophrenia, have been associated with increased morbidity
and mortality. Many studies are performed in specialized settings with a strong focus on schizophrenia. Somatic
comorbidity after psychosis is studied, using a general practice comorbidity registration network.
Methods: Hazard ratios are presented resulting from frailty models to assess the risk of subsequent somatic disease
after a diagnosis of psychosis compared to people without psychosis matched on practice, age and gender. Diseases
studied are cancer, physical trauma, diabetes mellitus, gastrointestinal disorders, joint disorders, irritable bowel
syndrome, general infections, metabolic disorders other than diabetes, hearing and vision problems, anemia,
cardiovascular disease, alcohol abuse, lung disorders, mouth and teeth problems, sexually transmitted diseases.
Results: Significant higher risks after a diagnosis of psychosis were found for the emergence of diabetes, physical
trauma, gastrointestinal disorders, alcohol abuse, chronic lung disease and teeth and mouth problems. With regard
to diabetes, by including the type of antipsychotic medication it is clear that the significant overall effect was
largely due to the use of atypical antipsychotic medication. No significant higher risk was seen for cancer, joint
conditions, irritable bowel syndrome, general infections, other metabolic conditions, hearing/vision problems,
anaemia, cardiovascular disease or diabetes, in case no atypical antipsychotic medication was used.
Conclusion: Significantly higher morbidity rates for some somatic conditions in patients with psychosis are
apparent. People with a diagnosis of psychosis benefit from regular assessments for the emergence of somatic
disorders and risk factors, including diabetes in case of atypical antipsychotic medication.
Background
Psychotic conditions and especially schizophrenia have
been associated with increased morbidity and mortality
[1,2]. Overall mortality among patients with schizophrenia
is reported to be about twice that in the general popula-
tion [3]. Higher comorbidity can come from the illness
itself and its consequences (e.g. lifestyle), medication use
or neglect by the medical profession with regard to ade-
quate screening and treatment for somatic comorbidity
[4]. A number of reasons can account for this neglect, and
the stigma related to psychiatric disorders is probably one
of them [2].
We used data from Intego, a GP-based morbidity
registration network in Flanders to study the incidence
of subsequent somatic diseases in psychosis patients and
to compare them to matched controls. Results can pro-
vide evidence to support or reject hypotheses found in
literature. Based on literature, we expected increased
incidences of general infections, physical trauma, meta-
bolic conditions, gastro-intestinal and joint conditions,
cardiovascular disease, alcohol abuse, chronic lung dis-
ease due to smoking, teeth- and mouth problems, and
sexually transmitted diseases (STDs) [2,5,6].
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Methods
Subjects and definitions
Data were obtained from Intego, a general practice-based
morbidity registration network in Belgium, established at
the Department of General Practice of the Katholieke Uni-
versiteit Leuven in 1994. The network provides data on
the incidence and prevalence of all diseases presented to
the GP either directly or through information provided by
specialist consultation, in the case of psychosis most com-
monly a psychiatrist. Next to this, drug prescriptions and
laboratory test results as well as some background infor-
mation are recorded. GPs are selected to be included in
the network on the basis of outstanding registration qual-
ity to maximize the validity and reliability of the data. By
the end of 2007, the Intego database contained 86 GPs
with over 2.1 million diagnoses in 197,000 different
patients and covered more than 1.5% of the population in
Flanders, the northern part of Belgium [7]. The population
is representative for the Flemish population with regard to
age, sex and socio-economic factors (SES). Data are
recorded using a detailed internal thesaurus and subse-
quently classified according to ICPC-2 (International Clas-
sification of Primary Care), a classification system for
morbidity in general practice accepted and used worldwide
[8].
In this retrospective cohort study we considered the
first episode of psychosis at all ages. Psychosis was
defined as Schizophrenia, (ICPC-2 P72), Affective Psy-
chosis (ICPC-2 P73), or Psychosis, NOS (ICPC-2 P98)
taken together. All first diagnoses of psychosis from
1994-2007 coded in the above mentioned categories were
used as the basis of the analysis (Table 1).
Cases were ascertained on the basis of the GP’s deci-
sion: this could be his own diagnosis based on routinely
collected data or based on a letter from the patient’s
psychiatrist. A patient was included as a case if he/she
had at least one diagnosis in the categories mentioned
above. Patients with organic psychosis or dementia were
excluded from the analysis.
To assess the possible subsequent disease categories we
combined diseases into meaningful outcome categories.
These groups were also based on the ICPC-2 classification.
Disease categories were defined on the basis of expert
advice. Atypical antipsychotics were defined as ATC-class
N05AH and N05AX.
Statistical analysis
The risk of developing subsequent disease in patients with
and without psychosis was analysed. All disease groups
were analysed as possible consequences of psychosis.
Patients who had a new diagnosis of a psychotic episode
during the registration period (1 January 1994 to 31
December 2007), using the date of diagnosis as the base-
line date, were included as cases. Non-psychosis patients
were matched on age (with a range from plus and minus 5
years), gender, within a practice to create control subjects.
The date of diagnosis of the index patient was assigned to
the matched patients as a baseline date for the study.
Therefore this date needed to fall within the first and last
year a control was seen by the GP. Double use of control
patients was not allowed. Patients with the particular dis-
ease before the psychosis date or matching date were
excluded. We aimed for five controls to be selected for
each case [9]. Both groups of patients were followed until
they had an event or were censored at July 1st 2007.
For every disease the unadjusted hazard ratio for the
association between psychosis and the disease was calcu-
lated (not controlled for age and gender).
Frailty proportional hazards analysis was used to iden-
tify the risk of a first episode of a somatic disease in
Table 1 Case definitions for ICPC-2 codes P72, P73 and P98
ICPC-2
ICD-
10
Schizophrenia (P72) Affective Psychosis
(P73)
Psychosis, NOS (P98)
F20 Schizophrenia
F21 Schizotypal disorder
F22 Persistent delusional disorder
F24 Induced delusional disorder
F25 Schizoaffective disorder
F28 Other nonorganic psychotic disorder
F29 Unspecified nonorganic psychotic
disorder
F30 Manic episode
F31 Bipolar affective disorder
F34.0 Cyclothymia
F23 Acute and transient psychotic disorder
F53.1 Severe mental and behavioural disorder associated with the
puerperium
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patients with psychosis and matched controls without
psychosis. Because of the association among the failure
time data that might exist within different matches, these
were modeled as random effect [10]. Random effect mod-
els have been used successfully in the analysis of corre-
lated failure times. The approach assumed that there
exists a common and unobserved latent variable, also
called frailty, that characterizes the relationship or depen-
dence of the correlated failure times [11]. The following
simple frailty model was used:
hij (t) = h0 (t) exp
(
β1Pij + β2Aij + β3Sij + vi
)
where h0(t) is the baseline hazard, b1-3 are the regression
coefficients and vi is the unobserved random effect for
every i-th match. Three covariates were used in the model:
a group indicator P to denote whether a patient had
experienced a psychosis or not, A for age at diagnosis for
psychosis and S for the gender of the subject. To obtain
consistent estimates, first the distribution was approxi-
mated by using piecewise baseline hazards based on esti-
mated quantized intervals [12]. The model is then fitted
using Gaussian quadrature in SAS PROC NLMIXED,
using a normal distribution for the random effect [13].
For the analysis of diabetes, we stratified for the use of
atypical versus other antipsychotic drugs [14].
To provide insight into a possible follow-up bias, data
were calculated on the follow-up time of psychotic
patients: are patients with a psychosis less inclined to visit
their GP? Does this change after the diagnosis? We used
the total years before and after the diagnosis (or matched
date in case of the non-psychosis group) starting from
1994 and ending in 2008 and calculated in how many
years patients were seen at least once during a year by the
GP. For example if a patient was in the population in 1994
and still in 2008 and he/she had a psychosis diagnosis in
2003, the total years before was 9 and after 5. Let’s assume
this patient consulted the GP in 1999, 2000 and 2005 the
ratio of consultation would be 0.22 before the diagnosis
and 0.2 afterwards.
All statistical analyses were carried out using SAS, ver-
sion 9.1.3 (SAS Institute, Cary, NC).
Results
894 patients were diagnosed as suffering from a psychotic
illness. The mean age at diagnosis was 48.8 years (SD =
21); 47 percent were males. Detailed epidemiological data
are provided in another article [15]. The matched group
included 4010 patients and the mean age was 45.5 (SD =
19) years. Gender distribution was the same as in the psy-
chosis group.
Unadjusted (Table 2) and Adjusted (Table 3) hazard
ratios for the development of the diagnostic categories
in psychosis versus no psychosis subjects are shown.
Data for STDs were not analysed further because of the
small sample size (N = 42).
Significant higher risks after a diagnosis of psychosis
(table 3 bold) were found for the emergence of physical
Table 2 Unadjusted Hazard ratios for the risk of
subsequent disease after a diagnosis of psychosis
Is psychosis a risk factor for......? Hazard ratio (95% CI) †
Cancer 0.85 (0.51-1.42)
Physical trauma 1.69 (1.29-2.2)****
Diabetes (any antipsychotic medication) 1.48 (0.92-2.38)
Atypical antipsychotic Medication 2.74 (1.41-5.33)**
Other antipsychotic Medication 1.03 (0.57-1.87)
GI inflammation 1.38 (1.01-1.89)*
Joint conditions 1.12 (0.86-1.45)
Irritable Bowel Syndrome 1.23 (0.25-6.10)
General infection 0.63 (0.34-1.16)
Metabolic conditions, no DM 0.97 (0.45-2.13)
Hearing/Vision 1.31 (0.75-2.29)
Anemia 0.68 (0.32-1.45)
Cardiovascular disease 0.93 (0.65-1.33)
Alcohol abuse 2.36 (1.14-4.86)*
Chronic lung disease 1.6 (1.17-2.38)**
Teeth- and mouth problems 1.58 (1.15-2.16)**
Sexually transmitted disease 4.48 (1.37-14.67)*
† Significant HRs are put in bold. *: p < 0.05; **: p < 0.01; ***: p < 0.001;****:
p < 0.0001
Table 3 Hazard ratios for the risk of subsequent disease
after a diagnosis of psychosis
Is psychosis a risk factor for......? Hazard ratio (95% CI) †
Cancer 0.94 (0.56-1.58)
Physical trauma 1.72 (1.31-2.25)****
Diabetes (any antipsychotic medication) 1.77 (1.11-2.83)*
Atypical antipsychotic Medication 2.46 (1.29-4.71)**
Other antipsychotic Medication 0.94 (0.52-1.69)
GI inflammation 1.44 (1.04-1.98)*
Joint conditions 1.16 (0.88-1.52)
Irritable Bowel Syndrome 2.08 (0.57-7.59)
General infection 0.66 (0.36-1.22)
Metabolic conditions, no DM 1.11 (0.50-2.46)
Hearing/Vision 1.52 (0.87-2.65)
Anemia 0.89 (0.46-1.70)
Cardiovascular disease 1.02 (0.70-1.47)
Alcohol abuse 2.27 (1.10-4.69)*
Chronic lung disease 1.72 (1.20-2.47)**
Teeth- and mouth problems 1.63 (1.18-2.24)**
Sexually transmitted disease -
† Significant HRs are put in bold. *: p < 0.05; **: p < 0.01; ***: p < 0.001;****:
p < 0.0001
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trauma (HR = 1.72 (95% CI = [(1.31,2.25)]); GI inflam-
mation (HR = 1.44 (95% CI = [1.04,1.98]); alcohol abuse
(HR = 2.27 (95% CI = [1.10,4.69]); chronic lung disease
(HR = 1.72 (95% CI = [1.20,2.47]) and teeth and mouth
problems (HR = 1.63 (95% CI = [1.18,2.24]).
More than 22% of these patients, diagnosed with psy-
chotic illness, were treated with atypical antipsychotics,
45% with other antipsychotics, and 16% have received
both. With regard to diabetes, by including the type of
antipsychotic medication it was clear the significant overall
effect (HR = 1.77 (95% CI = [(1.11,2.83)]) was largely due
to the use of atypical antipsychotic medication (Figure 1).
When this was entered in the model the effect of psychosis
disappears and the effect of the atypical medication
emerged (HR atypical medication = 2.46 (95% CI =
[(1.29,4.71)]). Next to diabetes we also found a significant
association of atypical medication and physical trauma
(HR atypical medication = 1.82 (95% CI = [1.21, 2.75]).
With regard to other antipsychotic medication an associa-
tion was found with cardiovascular disease (HR = 1.6 (95%
CI = [1.07,2.4]), alcohol abuse (HR = 4, 95% CI = [1.7,
9.4]) and mouth-and teeth problems (HR = 1.7, 95% CI =
[1.16, 2.46]).
No significant higher risk was seen for cancer, joint
conditions, IBS, general infections, other metabolic
conditions, hearing/vision problems, anaemia and cardi-
ovascular disease.
The follow-up time of patients showed consultation
rates (95% CI) before diagnosis of psychosis (matched date
in case of non-psychosis group) of 0.93 (0.92-0.94) for
cases and 0.86 (0.85-0.87) for controls [16]. After diagnosis
this was 0.89 (0.88-0.91) for cases and 0.84 (0.83-0.85) for
matched controls.
Discussion
Our study based on a large GP-based morbidity database
indicates significantly higher morbidity rates for some
somatic conditions in patients with psychosis: diabetes,
physical trauma, GI inflammation, alcohol abuse, chronic
lung disease and mouth and teeth problems, but surpris-
ingly not for cardiovascular disease, although from litera-
ture this could be expected [17]. A similar study to ours
however also found that older patients with psychotic
disorders are diagnosed with cardiovascular diseases less
frequently than other types of elderly patients. For
younger patients there was no difference [16]. It could be
hypothesized that the follow-up period is still too short
for cardiovascular disease to emerge because a long per-
iod of exposure to risk factors is needed before cardiovas-
cular disease emerges and/or that due to excess mortality
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in the psychosis group there is a selection bias. The rela-
tion requires further study. Many studies have found that
patients with schizophrenia have increased rates of sev-
eral chronic medical conditions, including coronary
artery disease, chronic obstructive pulmonary disease,
HIV, hepatitis C, and diabetes mellitus [18-20]. Goff et al.
concluded that these are potentially reversible and pre-
ventable and that identifying and modifying risk factors
could substantially improve the health of patients with
schizophrenia [21]. Several hypotheses for this increased
morbidity can be thought of. Patients with psychosis can
be less inclined to take care of themselves. There is a
high prevalence of smoking, obesity, poor diet, and
sedentary lifestyle among patients with schizophrenia
[22]. Adverse effects of antipsychotic medication may
play a role [18], as was confirmed in this study and pre-
vious ones for atypical antipsychotics and subsequent
diabetes [23,24]. It has been proposed that higher levels
of psychiatric symptoms might lead to more somatic
comorbidity because poor attention and poor insight
might create an inability to self-monitor and follow medi-
cal regimens [19]. Careful follow-up might be a crucial
factor with these patients.
Intego-data are representative for the Flemish popula-
tion with regard to age, gender and SES. However to date
no sufficient information is available on several lifestyle
variables, such as smoking, which influences several
chronic comorbid conditions [1,21]. We did not include
data on weight or BMI, to investigate the relation between
antipsychotic treatment, weight gain and diabetes. Because
of the study design, the frequency of follow-up of weight,
would not suffice to answer this relationship. Many of
these events occur quite rapid after initiation of drug treat-
ment and close monitoring is therefore needed [25]. To
date, also no mortality data can be provided. Most other
studies on somatic comorbidity in psychosis patients are
cross-sectional, based in specialised settings, or using only
younger schizophrenia patients. Because this study is a ret-
rospective cohort study it can capture important longitudi-
nal associations between psychosis and the development of
somatic comorbidity over the whole population. We
assume most diagnoses of psychosis in community dwell-
ing people are known by the GP, either be it by their own
diagnostic processes or via the diagnosis of a psychiatrist
or hospital staff, which is transferred to the GP (however
no quantitative data is available on this). A small number
of institutionalized patients might ‘disappear’, however, in
chronic psychiatric care without GP’s involvement.
Conclusion
Significantly higher morbidity rates for some somatic
conditions in patients with psychosis are apparent. Peo-
ple with a diagnosis of psychosis benefit from regular
assessments for the emergence of somatic disorders and
risk factors, including diabetes in case of atypical antipsy-
chotic medication. Primary care physicians should play
an active role in ensuring that patients with mental ill-
ness are thoroughly followed. Because of the possible
comorbidity shared care with other specialists such as
psychiatrists, diabetologists, specialist nurses or other
specialists should be established when necessary.
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